Working… Menu
Trial record 98 of 157 for:    Idiopathic Dilated Cardiomyopathy

Optimizing Left Ventricular Lead To Improve Cardiac Output (CARE/VOLCANO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01399801
Recruitment Status : Unknown
Verified July 2012 by Dusan Kocovic, M.D.,, Main Line Health.
Recruitment status was:  Recruiting
First Posted : July 22, 2011
Last Update Posted : July 18, 2012
Information provided by (Responsible Party):
Dusan Kocovic, M.D.,, Main Line Health

Brief Summary:

The purpose of this study is to determine if optimal lead placement, guided by the largest improvement in aortic flow measured by Doppler will:

  1. Improve the way the heart's left ventricle functions
  2. Decrease the number of hospital admissions for heart failure related symptoms
  3. Reduces uncoordinated heart contractions
  4. Improve quality of life as measured by the Minnesota Living with Heart Failure Questionaire and NYHA Class assessed after six months

Condition or disease Intervention/treatment Phase
Ischemic Congestive Cardiomyopathy Dilated Cardiomyopathy Congestive Heart Failure Procedure: Doppler flow measurement Procedure: standard implantation of the LV lead Not Applicable

Detailed Description:

The hypothesis of this study determines if response to CRT therapy could be improved by optimizing LV lead position at the time of the left ventricular pacing lead implantation. This optimization (using a Doppler wire) would alter the left ventricular activation pattern and contraction mechanics. This increase in contractility may improve the likelihood of mid/long term response to therapy. This study will compare 6-month response to CRT (left ventricular ejection fraction, decrease in left ventricular end systolic and end diastolic dimensions and volumes) in heart failure patients.

The secondary objective will be to:

  1. To determine if optimal lead placement, guided by the largest improvement in stroke volume, results in a greater 6-month improvement in clinical QOL and NYHA class.
  2. Acutely compare and/or correlate intra-operative A-V and V-V timing optimization via invasive pressure volume data to post-operative echo optimization of these same parameters.
  3. Acutely contrast changes in stroke volume during pacing from several different left ventricular lead locations.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Optimizing the Left Ventricular Contractility in Cardiac Resynchronization Therapy Using a Doppler Wire
Study Start Date : December 2010
Estimated Primary Completion Date : December 2012
Estimated Study Completion Date : June 2013

Arm Intervention/treatment
Experimental: hemodynamicaly guided LV lead placement
optimized left ventricular lead placement
Procedure: Doppler flow measurement
use of doppler wire to measure change in flow that corresponds to changes in stroke volume to guide LV lead placement

Active Comparator: Standard lead placement
Standard LV lead placement with no measurements to guide LV lead placement
Procedure: standard implantation of the LV lead
Standard implantation of the LV lead with measurements of flow

Primary Outcome Measures :
  1. Change in Left Ventricular End Systolic Volume (LVESV) using the difference from baseline to six months [ Time Frame: Six months ]
    Comparison of clinical and functional outcomes of stroke volume optimized lead placement to standard lateral lead placement.

Secondary Outcome Measures :
  1. Change in End diastolic volume [ Time Frame: Six months ]
    End diastolic volume should decrease over follow up time of six months as a result of left ventricular remodeling.

  2. Change in ejection fraction [ Time Frame: six months ]
    Increase in ejection fraction should happen as a result of remodeling and increased efficiency of the left ventricle

  3. Increase in exercise capacity [ Time Frame: six months ]
    Inrease in exercise capacity should be result of remodeled left ventricle and increased stroke volume and cardiac output

  4. Decrease in heart failure related hospital admissions [ Time Frame: six months ]
    number of hospitalizations for CHF should decrease during follow up

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical indication for CRT-P or CRT-D
  • QRS Duration>=120 MSEC
  • Left Ventricular Ejection fraction<=35%
  • NYHA Class III-IV
  • History of Cardiomyopathy, least one month post MI, or at least six months old in case of non-ischemic cardiomyopathy
  • At least 18 years of afe

Exclusion Criteria:

  • Previous implanted CRT-P/CRT-D
  • woman who are pregnant
  • Psychological or emotional problems

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01399801

Layout table for location contacts
Contact: Dusan Kocovic, MD 610-649-6980
Contact: Nancy Britton, RN 484-476-8578

Layout table for location information
United States, Pennsylvania
Lankenau Hosspital Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Dusan Kocovic, MD    610-649-6980   
Contact: Nancy Britton, RN    484-476-8578   
Principal Investigator: Kocovic Dusan, MD         
Sponsors and Collaborators
Main Line Health
Layout table for investigator information
Principal Investigator: Dusan Kocovic, MD Lankenau Hospital

Layout table for additonal information
Responsible Party: Dusan Kocovic, M.D.,, Dusan Kocovic, MD, Main Line Health Identifier: NCT01399801     History of Changes
Other Study ID Numbers: F/N-R09-284IL
First Posted: July 22, 2011    Key Record Dates
Last Update Posted: July 18, 2012
Last Verified: July 2012
Keywords provided by Dusan Kocovic, M.D.,, Main Line Health:
Cardiac Resynchronization Therapy
medically refractory heart failure patients
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Cardiomyopathy, Dilated
Heart Diseases
Cardiovascular Diseases